文献速递银屑病与炎症性皮肤病

阿普米司特与甲氨蝶呤在银屑病中的药物留存率:法国全国队列真实世界分析

Persistence of apremilast in moderate-to-severe psoriasis: a real-world analysis of 14 147 apremilast- and methotrexate-naive patients in the French National Health Insurance database.
PubMed 文献 · Br J Dermatol · 2019-07-22

该研究基于法国国家健康保险数据库2009–2017年数据,纳入14 147例未使用过阿普米司特和甲氨蝶呤的成人银屑病患者。

要点

  • 在真实世界队列中,阿普米司特1年停药率(69%)高于甲氨蝶呤(59%)。
  • 选择一线系统治疗时,医生应结合此停药风险差异进行决策。

核心结论

  • 真实世界数据显示,治疗第一年阿普米司特停药率显著高于甲氨蝶呤,且与既往治疗线数无关。

研究设计与样本

  • 基于法国国家健康保险数据库(Système National des Données de Santé)2009–2017年的全国性人口队列研究。
  • 采用倾向评分匹配的Cox模型比较药物留存率,匹配变量包括年龄、性别、银屑病关节炎、合并症及既往外用和系统治疗暴露。
  • 匹配后两组各纳入4805例基线特征相似的患者。

主要发现

  • Kaplan-Meier生存分析显示,治疗第一年阿普米司特停药率为69%,甲氨蝶呤为59%。
  • 匹配队列中,阿普米司特组3207例、甲氨蝶呤组2736例停止治疗。

临床怎么用

  • 在每日临床实践中,医生在甲氨蝶呤与阿普米司特之间选择一线系统治疗时,应考虑到阿普米司特停药风险更高的真实世界证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Real-world data on the persistence of apremilast vs. methotrexate are inconclusive. OBJECTIVES: To assess and compare the long-term persistence of apremilast and methotrexate in a large cohort of patients with psoriasis. METHODS: All adult patients with psoriasis registered in the French national health insurance database ('Système National des Données de Santé') between 2009 and 2017 were eligible for inclusion. The study population comprised apremilast- and methotrexate-naive patients, defined as those with a first prescription of apremilast or methotrexate. Levels of persistence were compared using a Cox model with propensity-score matching that included potential confounders (notably age, sex, psoriatic arthritis, comorbidities and previous exposure to topical and systemic treatments). RESULTS: In this nationwide population-based cohort, 14 147 adult patients with psoriasis (mean age 52·3 years, 55·2% male) were found to be naive to both apremilast and methotrexate. After propensity-score matching, two subgroups of 4805 patients with similar baseline characteristics were included, of whom 3207 apremilast-treated patients and 2736 methotrexate-treated patients discontinued their treatment. Kaplan-Meier survival propensity-score analyses revealed a discontinuation rate of 69% for apremilast and 59% for methotrexate in the first year of treatment. Apremilast-treated patients had a higher risk of discontinuation than methotrexate-treated patients when considering the study population as a whole (hazard ratio 1·28, 95% confidence interval 1·23-1·34) or in a propensity-score-matched analysis (hazard ratio 1·34, 95% confidence interval 1·27-1·41; P < 0·001). CONCLUSIONS: Our real-world data suggest that in the first year of treatment, the discontinuation rate was significantly higher for apremilast-treated patients than for methotrexate-treated patients, regardless of the previous therapeutic lines received. What's already known about this topic? Psoriasis is a common chronic, relapse-remitting, inflammatory skin disease associated with severe psychosocial impact. Apremilast, a phosphodiesterase 4 inhibitor, is one of the most recently commercialized psoriasis drugs. Little is known about the long-term clinical effectiveness of apremilast. What does this study add? The discontinuation rate at 1 year for apremilast was 69%, compared with 58% for methotrexate, in a nationwide population-based cohort including 14 147 nonselected adult patients with psoriasis. Patients in the apremilast cohort had a higher risk of discontinuation than patients in the methotrexate cohort using propensity-score matching, including potentially relevant individual risk factors such as age, sex, comorbidities and psoriatic arthritis, and regardless of the previous therapeutic lines received. In daily practice, physicians should take these results into account when choosing between methotrexate and apremilast as a first-line systemic therapy.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Sbidian E, Billionnet C, Weill A, et al. Persistence of apremilast in moderate-to-severe psoriasis: a real-world analysis of 14 147 apremilast- and methotrexate-naive patients in the French National Health Insurance database. Br J Dermatol. 2019. PMID: 31021438. doi:10.1111/bjd.18047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。